Bibliography
- ONO SJ, ABELSON MB: Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J. Allergy Clin. Immunol (2005) 115(1):118–122.
- FRIEDLAENDER MH: The current and future therapy of allergic conjunctivitis. Curr. Opin. Ophthalmol (1998) 9:54–58.
- BIELORY L: Ocular allergy guidelines: a practical treatment algorithm. Drugs (2002) 62(11):1611–1634.
- STAHL JL, BARNEY NP: Ocular allergic disease. Curr. Opin. Allergy Clin. Immunol (2004) 4(5):455–459.
- ZHAN H, SMITH L, CALDER V, BUCKLEY R, LIGHTMAN S: Clinical and immunological features of atopic keratoconjunctivitis. Int. Ophthalmol Clin. (2003) 43(1):59–71.
- OUSLER GW, WILCOX KA, GUPTA G, ABELSON MB: An evaluation of the ocular drying effects of 2 systemic antihistamines: loratadine and cetirizine hydrochloride. Ann. Allergy Asthma Immunol (2004) 93(5):460–464.
- SAMUDRE SS, LATTANZIO FRANK JR, WILLIAMS PB, SHEPPARD JD JR: Comparison of topical steroids for acute anterior uveitis. j Ocul Pharmacol Ther. (2004) 20(6):533–547.
- AKPEK EK, DART JK, WATSON S et al: A randomized trial of topical cyclosporine 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology (2004) 111:476–482.
- ROMANOWSKI EG, PLESS P, YATES KA, GORDON YJ: Topical cyclosporine A inhibits subepithelial immune infiltrates but also promotes viral shedding in experimental adenovirus models. Cornea (2005) 24:86–91.
- RIKKERS SM, HOLLAND GN, DRAYTON GE, MICHEL FK, TORRES MF, TAKAHASHI S: Topical tacrolimus treatment of atopic eyelid disease. Am. J. Ophthalmol (2003) 135(3):297–302.
- JOSEPH MA, KAUFMAN HE, INSLER M: Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders. Cornea (2005) 24:417–420.
- KATELARIS CH: Ocular allergy: implications for the clinical immunologist. Ann. Allergy Asthma Immunol (2003) 6(3):23–27.
- OETTGEN HC, GEHA RS: IgE in asthma and atopy: cellular and molecular connections. J. Clin. Invest. (1999) 104:829–835.
- BACON AS, AHULUWALIA P, IRANI AM et al.: Tear and conjunctival changes during the allergen-induced early-and late-phase responses. J. Allergy Clin. Immunol (2000) 106:948–954.
- BUHL R: Anti-IgE antibodies for the treatment of asthma. Curr. Opin. Pulm. Med. (2004) 11:27–34.
- BERGER W, GUPTA N, MCALARY M, FOWLER-TAYLOR A: Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann. Allergy Asthma Immunol. (2003) 91:182–188.
- NO AUTHORS LISTED: Xolair. In: Physicians Desk Reference. Duplay D (Ed.), Thompson PDR, Montvale, NJ, USA (2005):1359–1362.
- SCHIFFMAN RM, CHRISTIANSON MD, JACOBSEN G, HIRSCH JD, REIS BL: Reliability and validity of the ocular surface disease index. Arch. Ophthalmol. (2000)118:615–621.
- WILLIAMS PB, MCDONALD KW, SHEPPARD JD JR, LATTANZIO FA JR: Omalizumab for severe ocular allergy. J. Clin. Pharmacol (2004) 44:1200.
- WILLIAMS PB, SIMON DJ, SHEPPARD JD JR, LATTANZIO FA JR: Omalizumab improves symptoms of severe ocular allergy. Annual Meeting of the Association for Research in Vision and Ophthalmology. Fort Lauderdale, USA (2005) (also available from www.arvo.org).